Inovio Pharmaceuticals, Inc. (INO)
USD 1.45
(-8.54%)
USD 1.45
(-8.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.67 Million USD | -156.05% |
| 2022 | 4.76 Million USD | 261.24% |
| 2021 | -2.95 Million USD | 96.6% |
| 2020 | -86.83 Million USD | -3.49% |
| 2019 | -83.9 Million USD | -375.26% |
| 2018 | 30.48 Million USD | -27.8% |
| 2017 | 42.22 Million USD | 19.37% |
| 2016 | 35.36 Million USD | -12.83% |
| 2015 | 40.57 Million USD | 288.0% |
| 2014 | 10.45 Million USD | -22.35% |
| 2013 | 13.46 Million USD | 226.98% |
| 2012 | 4.11 Million USD | -57.95% |
| 2011 | 9.79 Million USD | 59.41% |
| 2010 | 6.14 Million USD | -32.62% |
| 2009 | 9.12 Million USD | 334.78% |
| 2008 | 2.09 Million USD | -56.37% |
| 2007 | 4.8 Million USD | 48.24% |
| 2006 | 3.24 Million USD | -38.35% |
| 2005 | 5.26 Million USD | 350.78% |
| 2004 | 1.16 Million USD | 1349.29% |
| 2003 | 80.52 Thousand USD | -57.51% |
| 2002 | 189.52 Thousand USD | -92.5% |
| 2001 | 2.52 Million USD | -30.17% |
| 2000 | 3.61 Million USD | -49.02% |
| 1999 | 7.1 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -727.86 Thousand USD | 4.19% |
| 2024 Q1 | -759.73 Thousand USD | -946.81% |
| 2023 FY | -2.67 Million USD | -156.05% |
| 2023 Q1 | -30.06 Million USD | -2356.36% |
| 2023 Q3 | -644.32 Thousand USD | 29.77% |
| 2023 Q4 | -72.57 Thousand USD | 88.74% |
| 2023 Q2 | -917.43 Thousand USD | 96.95% |
| 2022 Q4 | -1.22 Million USD | -115.71% |
| 2022 Q3 | 7.79 Million USD | 1345.48% |
| 2022 Q1 | -55.77 Million USD | -10228.28% |
| 2022 Q2 | -625.65 Thousand USD | 98.88% |
| 2022 FY | 4.76 Million USD | 261.24% |
| 2021 Q3 | -46.79 Million USD | 33.65% |
| 2021 Q1 | -38.67 Million USD | -86.63% |
| 2021 Q4 | -540.06 Thousand USD | 98.85% |
| 2021 FY | -2.95 Million USD | 96.6% |
| 2021 Q2 | -70.53 Million USD | -82.39% |
| 2020 Q3 | -26.21 Million USD | -18.59% |
| 2020 Q2 | -22.1 Million USD | -24.32% |
| 2020 Q4 | -20.72 Million USD | 20.97% |
| 2020 FY | -86.83 Million USD | -3.49% |
| 2020 Q1 | -17.78 Million USD | 10.29% |
| 2019 Q2 | -22.35 Million USD | -3.67% |
| 2019 Q1 | -21.55 Million USD | 9.65% |
| 2019 Q3 | -18.27 Million USD | 18.26% |
| 2019 Q4 | -19.82 Million USD | -8.51% |
| 2019 FY | -83.9 Million USD | -375.26% |
| 2018 Q2 | 1.98 Million USD | 108.62% |
| 2018 FY | 30.48 Million USD | -27.8% |
| 2018 Q1 | -23.04 Million USD | -45.38% |
| 2018 Q3 | -19.85 Million USD | -1099.48% |
| 2018 Q4 | -23.86 Million USD | -20.21% |
| 2017 Q2 | -3.46 Million USD | 75.53% |
| 2017 Q4 | -15.85 Million USD | 30.67% |
| 2017 FY | 42.22 Million USD | 19.37% |
| 2017 Q1 | -14.16 Million USD | 8.0% |
| 2017 Q3 | -22.86 Million USD | -559.59% |
| 2016 Q3 | -14.43 Million USD | -7.54% |
| 2016 Q2 | -13.42 Million USD | -33.22% |
| 2016 FY | 35.36 Million USD | -12.83% |
| 2016 Q4 | -15.39 Million USD | -6.63% |
| 2016 Q1 | -10.07 Million USD | -4.27% |
| 2015 FY | 40.57 Million USD | 288.0% |
| 2015 Q1 | -4.25 Million USD | 37.24% |
| 2015 Q2 | -11.4 Million USD | -167.67% |
| 2015 Q3 | 8.1 Million USD | 171.11% |
| 2015 Q4 | -9.66 Million USD | -219.22% |
| 2014 Q2 | -5.8 Million USD | 1.06% |
| 2014 Q1 | -5.86 Million USD | -25.8% |
| 2014 Q3 | -5.17 Million USD | 10.82% |
| 2014 Q4 | -6.78 Million USD | -31.09% |
| 2014 FY | 10.45 Million USD | -22.35% |
| 2013 Q2 | -3.62 Million USD | 0.94% |
| 2013 Q4 | -4.66 Million USD | -215.21% |
| 2013 Q3 | 4.04 Million USD | 211.67% |
| 2013 FY | 13.46 Million USD | 226.98% |
| 2013 Q1 | -3.65 Million USD | -10.63% |
| 2012 Q3 | -4.11 Million USD | -1044.23% |
| 2012 FY | 4.11 Million USD | -57.95% |
| 2012 Q1 | 1.69 Million USD | 3.7% |
| 2012 Q2 | 436.08 Thousand USD | -74.24% |
| 2012 Q4 | -3.3 Million USD | 19.66% |
| 2011 Q3 | 2.63 Million USD | 9.0% |
| 2011 Q4 | 1.63 Million USD | -38.1% |
| 2011 FY | 9.79 Million USD | 59.41% |
| 2011 Q1 | 3.1 Million USD | 31.58% |
| 2011 Q2 | 2.41 Million USD | -22.08% |
| 2010 Q1 | 1.37 Million USD | -47.43% |
| 2010 Q4 | 2.35 Million USD | 84.87% |
| 2010 Q3 | 1.27 Million USD | 12.48% |
| 2010 Q2 | 1.13 Million USD | -17.37% |
| 2010 FY | 6.14 Million USD | -32.62% |
| 2009 Q3 | 3.64 Million USD | 46.35% |
| 2009 FY | 9.12 Million USD | 334.78% |
| 2009 Q2 | 2.49 Million USD | 574.4% |
| 2009 Q1 | 369.45 Thousand USD | 13.03% |
| 2009 Q4 | 2.61 Million USD | -28.35% |
| 2008 Q1 | 653.01 Thousand USD | -80.34% |
| 2008 FY | 2.09 Million USD | -56.37% |
| 2008 Q4 | 326.84 Thousand USD | -28.12% |
| 2008 Q3 | 454.73 Thousand USD | -31.42% |
| 2008 Q2 | 663.03 Thousand USD | 1.53% |
| 2007 FY | 4.8 Million USD | 48.24% |
| 2007 Q2 | 439.32 Thousand USD | -1.86% |
| 2007 Q1 | 447.65 Thousand USD | -65.74% |
| 2007 Q3 | 486.51 Thousand USD | 10.74% |
| 2007 Q4 | 3.32 Million USD | 582.77% |
| 2006 Q3 | 519.57 Thousand USD | -14.32% |
| 2006 Q2 | 606.44 Thousand USD | -5.5% |
| 2006 FY | 3.24 Million USD | -38.35% |
| 2006 Q1 | 641.74 Thousand USD | 3.01% |
| 2006 Q4 | 1.3 Million USD | 151.49% |
| 2005 FY | 5.26 Million USD | 350.78% |
| 2005 Q1 | 961.92 Thousand USD | 77.23% |
| 2005 Q2 | 2.89 Million USD | 201.0% |
| 2005 Q3 | 668.23 Thousand USD | -76.92% |
| 2005 Q4 | 622.98 Thousand USD | -6.77% |
| 2004 Q4 | 542.73 Thousand USD | 19.24% |
| 2004 Q3 | 455.15 Thousand USD | 355.98% |
| 2004 FY | 1.16 Million USD | 1349.29% |
| 2004 Q2 | 99.81 Thousand USD | 43.86% |
| 2004 Q1 | 69.38 Thousand USD | 82.22% |
| 2003 Q1 | 11.13 Thousand USD | 104.63% |
| 2003 FY | 80.52 Thousand USD | -57.51% |
| 2003 Q4 | 38.07 Thousand USD | 70.66% |
| 2003 Q3 | 22.31 Thousand USD | 147.79% |
| 2003 Q2 | 9004.00 USD | -19.15% |
| 2002 FY | 189.52 Thousand USD | -92.5% |
| 2002 Q4 | -240.34 Thousand USD | -454.03% |
| 2002 Q3 | 67.88 Thousand USD | 65.7% |
| 2002 Q2 | 40.97 Thousand USD | -91.37% |
| 2002 Q1 | 474.99 Thousand USD | 113.43% |
| 2001 Q1 | 1.12 Million USD | 28.77% |
| 2001 FY | 2.52 Million USD | -30.17% |
| 2001 Q4 | 222.55 Thousand USD | -68.64% |
| 2001 Q3 | 709.75 Thousand USD | 50.82% |
| 2001 Q2 | 470.6 Thousand USD | -58.16% |
| 2000 Q3 | 908.51 Thousand USD | -2.61% |
| 2000 Q1 | 919.79 Thousand USD | 2.2% |
| 2000 FY | 3.61 Million USD | -49.02% |
| 2000 Q4 | 873.55 Thousand USD | -3.85% |
| 2000 Q2 | 932.85 Thousand USD | 1.42% |
| 1999 Q1 | 4.9 Million USD | 600.0% |
| 1999 Q2 | 700 Thousand USD | -85.71% |
| 1999 FY | 7.1 Million USD | 0.0% |
| 1999 Q4 | 900 Thousand USD | -25.0% |
| 1999 Q3 | 1.2 Million USD | 71.43% |
| 1998 Q4 | 700 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.176% |
| AlloVir, Inc. | -398 Thousand USD | -571.238% |
| Aptorum Group Limited | -1.11 Million USD | -139.666% |
| Ardelyx, Inc. | 106.66 Million USD | 102.505% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 101.11% |
| Bicycle Therapeutics plc | -129.52 Million USD | 97.937% |
| AbCellera Biologics Inc. | 38.02 Million USD | 107.026% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | 2326.273% |
| Chimerix, Inc. | 324 Thousand USD | 924.546% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 91.429% |
| Elevation Oncology, Inc. | -39 Thousand USD | -6750.072% |
| Alkermes plc | 1.37 Billion USD | 100.194% |
| Fortress Biotech, Inc. | 57.85 Million USD | 104.618% |
| Fortress Biotech, Inc. | 57.85 Million USD | 104.618% |
| Agenus Inc. | 139.61 Million USD | 101.913% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 116.116% |
| Dyadic International, Inc. | 922.95 Thousand USD | 389.453% |
| ImmuCell Corporation | 4.39 Million USD | 160.768% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 112.685% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 97.483% |
| Lantern Pharma Inc. | -174.84 Thousand USD | -1427.958% |
| Immix Biopharma, Inc. | -5468.00 USD | -48757.498% |
| Incyte Corporation | 3.44 Billion USD | 100.078% |
| IO Biotech, Inc. | -756 Thousand USD | -253.377% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 94.296% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 80.0% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | -5945.822% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 97.28% |
| Keros Therapeutics, Inc. | -664 Thousand USD | -302.339% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | -4757.324% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | -53330.56% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 102.231% |
| ContextLogic Inc. | 59 Million USD | 104.528% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | 433.108% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | -406.931% |
| MiMedx Group, Inc. | 266.84 Million USD | 101.001% |
| MEI Pharma, Inc. | 49.32 Million USD | 105.416% |
| Novavax, Inc. | 639.93 Million USD | 100.417% |
| NextCure, Inc. | -3.68 Million USD | 27.483% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 114.029% |
| Onconetix, Inc. | -1.12 Million USD | -137.013% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 90.778% |
| Opthea Limited | 21.72 Thousand USD | 12399.853% |
| Psyence Biomedical Ltd. | -240.00 USD | -1113036.667% |
| Vaxcyte, Inc. | -75 Million USD | 96.438% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | -4560.238% |
| Precigen, Inc. | 106 Thousand USD | 2620.309% |
| Pharming Group N.V. | 220.1 Million USD | 101.214% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | 618.743% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | 364.77% |
| PureTech Health plc | -1.6 Million USD | -66.658% |
| Pyxis Oncology, Inc. | -2 Million USD | -33.576% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 102.434% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 98.527% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | -416.991% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | Infinity% |
| Seer, Inc. | 7.02 Million USD | 138.018% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 94.106% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 87.85% |
| Acelyrin, Inc. | -115 Thousand USD | -2223.068% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | -26479.723% |
| SELLAS Life Sciences Group, Inc. | - USD | Infinity% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | -367.868% |
| Senti Biosciences, Inc. | -2.68 Million USD | 0.428% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 133.941% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | 165.947% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 44.32% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 32.23% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 109.171% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | 638.615% |
| VYNE Therapeutics Inc. | 424 Thousand USD | 730.077% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -3157.961% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 102.566% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 101.975% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 97.244% |
| ChromaDex Corporation | 50.78 Million USD | 105.261% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 109.091% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -1051.521% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -442.993% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 96.557% |
| CRISPR Therapeutics AG | 240.95 Million USD | 101.109% |
| Precision BioSciences, Inc. | 40.47 Million USD | 106.601% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 97.278% |
| Innoviva, Inc. | 261.06 Million USD | 101.023% |
| Jaguar Health, Inc. | 7.72 Million USD | 134.587% |
| Summit Therapeutics Inc. | -2.05 Million USD | -30.318% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | 161.022% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 112.4% |
| ESSA Pharma Inc. | -118.49 Thousand USD | -2154.625% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | -1764.277% |
| GT Biopharma, Inc. | - USD | Infinity% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | 538.675% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 102.218% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 100.852% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | 203.789% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | -5165.132% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 62.362% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | -462.966% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | -25587.769% |
| Soligenix, Inc. | 97.31 Thousand USD | 2845.35% |
| Century Therapeutics, Inc. | -10.8 Million USD | 75.284% |
| Kura Oncology, Inc. | -849 Thousand USD | -214.668% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 96.019% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | -1717.366% |
| Ocean Biomedical, Inc. | - USD | Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 102.697% |
| Autolus Therapeutics plc | -4.86 Million USD | 45.109% |
| Mineralys Therapeutics, Inc. | - USD | Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 106.455% |
| Eterna Therapeutics Inc. | -168 Thousand USD | -1490.195% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 102.82% |
| GRI Bio, Inc. | 10.84 Million USD | 124.643% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | 205.179% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 69.247% |
| IGM Biosciences, Inc. | -211.66 Million USD | 98.738% |
| INmune Bio, Inc. | 155 Thousand USD | 1823.566% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 104.313% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | -77.358% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | -311.984% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | -9025.941% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | 764.559% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | -33.844% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -753.523% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 102.828% |
| Verastem, Inc. | -62 Thousand USD | -4208.916% |
| Abeona Therapeutics Inc. | 2.43 Million USD | 209.714% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | -923.574% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | 188.257% |
| Histogen Inc. | 3.76 Million USD | 170.882% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | 563.663% |
| Surrozen, Inc. | -27.23 Million USD | 90.189% |
| Organovo Holdings, Inc. | -5.38 Million USD | 50.426% |
| Lixte Biotechnology Holdings, Inc. | - USD | Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | -121.726% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 89.583% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 113.323% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | -134825.657% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 144.038% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | -3879.574% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 101.726% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | 1932.324% |
| Apollomics, Inc. | 127 Thousand USD | 2203.565% |
| Amarin Corporation plc | 165.54 Million USD | 101.614% |
| Mesoblast Limited | -9.81 Million USD | 72.781% |
| Turnstone Biologics Corp. | 16.5 Million USD | 116.185% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 97.582% |
| Synaptogenix, Inc. | -6347.00 USD | -41991.193% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | -5138.29% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 101.656% |
| BriaCell Therapeutics Corp. | - USD | Infinity% |
| Monopar Therapeutics Inc. | - USD | Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 100.152% |
| Better Therapeutics, Inc. | -2.72 Million USD | 2.106% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 97.618% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 100.79% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | -23318.022% |
| Dermata Therapeutics, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 57.324% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | -141.113% |
| TNF Pharmaceuticals, Inc. | - USD | Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 136.506% |
| Insmed Incorporated | 239.63 Million USD | 101.115% |
| Virpax Pharmaceuticals, Inc. | - USD | Infinity% |
| MediWound Ltd. | 3.57 Million USD | 174.665% |
| OmniAb, Inc. | 14.66 Million USD | 118.215% |
| Alector, Inc. | -95.05 Million USD | 97.189% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 102.127% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 93.853% |
| Zai Lab Limited | 170.9 Million USD | 101.563% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 103.263% |
| Aura Biosciences, Inc. | -1.29 Million USD | -106.296% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | 2155.022% |
| Immunic, Inc. | -111 Thousand USD | -2306.782% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 116.851% |
| Veracyte, Inc. | 248.14 Million USD | 101.077% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 99.962% |
| FibroGen, Inc. | 128.9 Million USD | 102.072% |
| SeaStar Medical Holding Corporation | - USD | Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | -473575.177% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 77.102% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 100.079% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | 786.768% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 100.752% |
| TG Therapeutics, Inc. | 219.1 Million USD | 101.219% |
| Galecto, Inc. | -830 Thousand USD | -221.871% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -92.89% |
| Fortrea Holdings Inc. | 424 Million USD | 100.63% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 96.9% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | -371.169% |
| XBiotech Inc. | -1.74 Million USD | -53.184% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | -141.113% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 94.251% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 96.463% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 103.64% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 115.899% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 100.687% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 94.619% |
| Vaxxinity, Inc. | -2.23 Million USD | -19.585% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 100.818% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 76.408% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 110.926% |
| NexImmune, Inc. | -1.02 Million USD | -160.644% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | 49572.741% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 62.403% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.024% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | -3897.678% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 24.767% |
| Ainos, Inc. | -253.73 Thousand USD | -952.889% |
| Pluri Inc. | 322 Thousand USD | 929.667% |
| Prothena Corporation plc | -129.2 Million USD | 97.932% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 105.298% |
| Celularity Inc. | 6.75 Million USD | 139.549% |
| Rallybio Corporation | -150 Thousand USD | -1681.019% |
| Cue Biopharma, Inc. | -32.6 Million USD | 91.807% |
| MeiraGTx Holdings plc | 287 Thousand USD | 1030.846% |
| Omeros Corporation | -69.77 Million USD | 96.171% |
| Humacyte, Inc. | -76.55 Million USD | 96.51% |
| Immunocore Holdings plc | 248.39 Million USD | 101.076% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 82.388% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 104.283% |
| Blueprint Medicines Corporation | 236.58 Million USD | 101.129% |
| CalciMedica, Inc. | -58 Thousand USD | -4506.083% |
| Cabaletta Bio, Inc. | -1.42 Million USD | -87.344% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 109.195% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 6.064% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 91.344% |
| Pulmatrix, Inc. | -8.22 Million USD | 67.5% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | -128.336% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | -569.556% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 99.33% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | 196.251% |
| Cytokinetics, Incorporated | -322.59 Million USD | 99.172% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | 409.884% |
| Protara Therapeutics, Inc. | -341 Thousand USD | -683.439% |
| Vor Biopharma Inc. | -3.49 Million USD | 23.496% |
| Roivant Sciences Ltd. | 109.23 Million USD | 102.446% |
| Evogene Ltd. | 1.39 Million USD | 290.96% |
| ProKidney Corp. | -3.16 Million USD | 15.698% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 93.916% |
| Hoth Therapeutics, Inc. | - USD | Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 138.961% |
| CorMedix Inc. | -205.56 Thousand USD | -1199.622% |
| BioLineRx Ltd. | 1.1 Million USD | 341.113% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 96.604% |
| Galectin Therapeutics Inc. | -33 Thousand USD | -7995.539% |
| Atai Life Sciences N.V. | -5000.00 USD | -53330.56% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | -2092.311% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | -2682.842% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | -92.335% |
| Sagimet Biosciences Inc. | 2 Million USD | 233.576% |
| MediciNova, Inc. | 979.7 Thousand USD | 372.687% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 96.832% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | -2725.369% |
| GeoVax Labs, Inc. | -20.72 Million USD | 87.107% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 101.092% |
| Biomea Fusion, Inc. | -4.2 Million USD | 36.407% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 100.306% |
| Mereo BioPharma Group plc | 7.42 Million USD | 135.975% |
| Cullinan Oncology, Inc. | -310 Thousand USD | -761.783% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | -22162.733% |
| Absci Corporation | -41.84 Million USD | 93.616% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | -53330.56% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 96.502% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | -8.555% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 101.25% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | -183.903% |
| Allakos Inc. | -6.14 Million USD | 56.497% |
| Imunon, Inc. | -720 Thousand USD | -271.043% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 96.128% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 100.561% |
| BioAtla, Inc. | -103.73 Million USD | 97.425% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | -23318.022% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -1400.858% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 98.9% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | -759.012% |
| XOMA Corporation | 3.86 Million USD | 169.193% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 96.188% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 118.058% |
| aTyr Pharma, Inc. | -2.38 Million USD | -11.873% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 121.441% |
| Akero Therapeutics, Inc. | -29 Thousand USD | -9112.166% |
| Viridian Therapeutics, Inc. | -1 Million USD | -165.033% |
| Eliem Therapeutics, Inc. | - USD | Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | 20550315.385% |
| Akari Therapeutics, Plc | -4000.00 USD | -66688.2% |
| Tevogen Bio Holdings Inc. | - USD | Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.419% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | 1472.069% |
| UroGen Pharma Ltd. | 73.35 Million USD | 103.642% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 89.992% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 23110.577% |
| Orgenesis Inc. | -5.72 Million USD | 53.336% |
| Entera Bio Ltd. | -56 Thousand USD | -4670.586% |
| GH Research PLC | -315 Thousand USD | -748.104% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | -1313.507% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | -408.862% |
| Xencor, Inc. | -85.26 Million USD | 96.867% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | -1108.962% |
| Replimune Group, Inc. | -2.65 Million USD | -0.623% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | -166.823% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 101.502% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | 1472.069% |
| Portage Biotech Inc. | -54 Thousand USD | -4847.274% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | -2725.369% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | -608.628% |
| OncoCyte Corporation | 413 Thousand USD | 746.859% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | -59333.326% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | -1203290.991% |
| Purple Biotech Ltd. | -196 Thousand USD | -1263.024% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 129.79% |
| scPharmaceuticals Inc. | 9.78 Million USD | 127.311% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 74.423% |
| HilleVax, Inc. | -2.15 Million USD | -23.911% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | -2654.153% |
| Tharimmune, Inc. | - USD | Infinity% |
| Genprex, Inc. | -15 Thousand USD | -17705.439% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | -299.929% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | -11515.339% |
| XTL Biopharmaceuticals Ltd. | - USD | Infinity% |
| Virios Therapeutics, Inc. | - USD | Infinity% |
| OKYO Pharma Limited | -7506.16 USD | -35491.141% |
| Savara Inc. | -44.26 Million USD | 93.964% |
| Curis, Inc. | 9.81 Million USD | 127.23% |
| Daré Bioscience, Inc. | 2.76 Million USD | 196.462% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | -2040.853% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | -54.513% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | -1071.723% |
| BeiGene, Ltd. | 2.07 Billion USD | 100.129% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 4.448% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 99.332% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 104.713% |
| Erasca, Inc. | -3.73 Million USD | 28.416% |
| bluebird bio, Inc. | -4.03 Million USD | 33.709% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | -9367.46% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.14% |
| DBV Technologies S.A. | 15.72 Million USD | 116.986% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | -9367.46% |
| Moderna, Inc. | 2.15 Billion USD | 100.124% |
| Vincerx Pharma, Inc. | -915 Thousand USD | -191.97% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 133.369% |
| Molecular Templates, Inc. | 50.39 Million USD | 105.301% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | -398.419% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 101.997% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 57.063% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 93.21% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 97.596% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 25.543% |
| MacroGenics, Inc. | 50.52 Million USD | 105.287% |
| RenovoRx, Inc. | - USD | Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 56.19% |
| Prime Medicine, Inc. | -147.9 Million USD | 98.194% |
| Aditxt, Inc. | -111.66 Thousand USD | -2292.556% |
| Adagene Inc. | 18.11 Million USD | 114.75% |
| Estrella Immunopharma, Inc. | - USD | Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | 647.444% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 101.905% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 101.693% |
| SciSparc Ltd. | 2.19 Million USD | 221.654% |
| Vericel Corporation | 135.57 Million USD | 101.971% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | -10565.208% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | -8522.839% |
| Generation Bio Co. | -73.91 Million USD | 96.385% |
| Astria Therapeutics, Inc. | - USD | Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | -511.334% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 104.891% |
| Invivyd, Inc. | -2.02 Million USD | -31.732% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 99.112% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | -2482.734% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 102.772% |
| Artelo Biosciences, Inc. | - USD | Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 102.718% |
| ADMA Biologics, Inc. | 88.21 Million USD | 103.028% |
| Clene Inc. | 533 Thousand USD | 601.225% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 111.081% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | -179.157% |
| GeoVax Labs, Inc. | -20.72 Million USD | 87.107% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | 234.383% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | -1274.837% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 105.364% |
| Relmada Therapeutics, Inc. | - USD | Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 62.33% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | -219.561% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 103.203% |
| Evaxion Biotech A/S | 73.11 Thousand USD | 3754.021% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 105.025% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 98.457% |
| Trevena, Inc. | 1.45 Million USD | 283.61% |
| Surrozen, Inc. | -27.23 Million USD | 90.189% |
| Tyra Biosciences, Inc. | -353 Thousand USD | -656.807% |
| Cingulate Inc. | -582.91 Thousand USD | -358.303% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | -8517.832% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 86.438% |
| Tenax Therapeutics, Inc. | -7570.00 USD | -35190.991% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | -203.238% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 100.392% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | -170.398% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | -4641.628% |
| Kronos Bio, Inc. | 1.37 Million USD | 294.718% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 95.022% |
| CERo Therapeutics Holdings, Inc. | - USD | Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -814.907% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -447.092% |
| ImmunityBio, Inc. | -17.89 Million USD | 85.067% |
| Korro Bio, Inc. | -3.63 Million USD | 26.404% |
| Kineta, Inc. | 5.43 Million USD | 149.172% |
| BioVie Inc. | -229.37 Thousand USD | -1064.689% |
| Codexis, Inc. | 57.33 Million USD | 104.66% |
| Celularity Inc. | 6.75 Million USD | 139.549% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 166.572% |
| Celcuity Inc. | -142.77 Thousand USD | -1771.185% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | 5380.743% |
| Cibus, Inc. | 1.42 Million USD | 287.871% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | -614.312% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 88.344% |
| IN8bio, Inc. | -2.5 Million USD | -6.818% |
| Kodiak Sciences Inc. | -25.94 Million USD | 89.704% |
| Annexon, Inc. | -3.26 Million USD | 18.227% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | -30.701% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 93.599% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | 517.426% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.343% |
| Eyenovia, Inc. | - USD | Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 101.545% |
| Conduit Pharmaceuticals Inc. | - USD | Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | -40.607% |
| Arcellx, Inc. | 108.27 Million USD | 102.467% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 91.747% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 103.373% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 87.37% |
| Moolec Science SA | -143.3 Thousand USD | -1764.225% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 93.687% |
| Geron Corporation | -123.5 Million USD | 97.837% |
| LAVA Therapeutics N.V. | 3.28 Million USD | 181.276% |
| Royalty Pharma plc | 1.79 Billion USD | 100.149% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 96.188% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | -73862.569% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | 1254.551% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 97.602% |
| Humacyte, Inc. | -76.55 Million USD | 96.51% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | -181.458% |
| 89bio, Inc. | -273 Thousand USD | -878.582% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | -112.532% |
| Avenue Therapeutics, Inc. | - USD | Infinity% |
| Genelux Corporation | -848 Thousand USD | -215.039% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | -2071.974% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | 338.742% |
| Notable Labs, Ltd. | 113 Thousand USD | 2464.184% |
| Liquidia Corporation | 14.6 Million USD | 118.298% |
| Mustang Bio, Inc. | -2.22 Million USD | -20.069% |
| Immunovant, Inc. | -231 Thousand USD | -1056.506% |
| Quantum-Si incorporated | 488 Thousand USD | 647.444% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 95.192% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | -8805.093% |
| Vera Therapeutics, Inc. | 1.86 Million USD | 243.476% |
| Acasti Pharma Inc. | -11 Thousand USD | -24186.618% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | -1205.624% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | -311.984% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 98.405% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | 335.464% |
| NeuroBo Pharmaceuticals, Inc. | - USD | Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | -601.188% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | -36.442% |
| PepGen Inc. | -1.18 Million USD | -125.636% |
| Moleculin Biotech, Inc. | -127 Thousand USD | -2003.565% |
| United Therapeutics Corporation | 2.07 Billion USD | 100.129% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 88.332% |
| Solid Biosciences Inc. | -76.56 Million USD | 96.511% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | -3134.961% |
| Immuneering Corporation | -764.13 Thousand USD | -249.613% |
| Lixte Biotechnology Holdings, Inc. | - USD | Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | 4131.643% |
| Belite Bio, Inc | -399 Thousand USD | -569.556% |
| XOMA Corporation | 3.86 Million USD | 169.193% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 86.666% |
| Bionomics Limited | -434.44 Thousand USD | -514.923% |
| Apogee Therapeutics, Inc. | - USD | Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | -148.746% |
| uniQure N.V. | 2.21 Million USD | 220.611% |
| Cassava Sciences, Inc. | -89.42 Million USD | 97.012% |
| Estrella Immunopharma, Inc. | - USD | Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 97.098% |
| Forte Biosciences, Inc. | -9000.00 USD | -29583.644% |
| Anebulo Pharmaceuticals, Inc. | - USD | Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | -219.943% |
| Conduit Pharmaceuticals Inc. | - USD | Infinity% |
| SeaStar Medical Holding Corporation | - USD | Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | -511.334% |
| Altimmune, Inc. | -65.37 Million USD | 95.913% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 100.738% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | -148.746% |
| Compugen Ltd. | 31.45 Million USD | 108.493% |
| Peak Bio, Inc. | 367.76 Thousand USD | 826.415% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 110.897% |
| Benitec Biopharma Inc. | 108 Thousand USD | 2573.637% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | -3325.036% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | -122.072% |
| Zura Bio Limited | - USD | Infinity% |
| PolyPid Ltd. | -1.82 Million USD | -46.626% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | -2144.982% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | -122.072% |
| Instil Bio, Inc. | -4.75 Million USD | 43.828% |
| argenx SE | 1.1 Billion USD | 100.241% |
| Immunome, Inc. | -8.9 Million USD | 70.006% |
| Compass Therapeutics, Inc. | -1.89 Million USD | -41.351% |
| Verona Pharma plc | -679.62 Thousand USD | -293.089% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | -1426.587% |
| Shattuck Labs, Inc. | -2.38 Million USD | -12.014% |
| CervoMed Inc. | -1.29 Million USD | -106.515% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | -10.99% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 44.075% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | 208.115% |
| Moolec Science SA | -143.3 Thousand USD | -1764.225% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | -554.738% |
| AnaptysBio, Inc. | 14.78 Million USD | 118.074% |
| Design Therapeutics, Inc. | -537 Thousand USD | -397.491% |
| Leap Therapeutics, Inc. | -427 Thousand USD | -525.651% |
| NeurAxis, Inc. | 2.15 Million USD | 223.871% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | 224.489% |
| Lumos Pharma, Inc. | 2 Million USD | 233.111% |
| Achilles Therapeutics plc | -4.73 Million USD | 43.535% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | -1426.587% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | -2428.061% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 108.439% |
| CERo Therapeutics Holdings, Inc. | - USD | Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | 409.884% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | -158.869% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 94.135% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | 6312.856% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | -225.003% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | -20203.45% |
| Palisade Bio, Inc. | 246 Thousand USD | 1185.987% |
| Tourmaline Bio, Inc. | -33 Thousand USD | -7995.539% |
| Beam Therapeutics Inc. | -59.67 Million USD | 95.523% |
| Neurogene Inc. | -3.26 Million USD | 18.102% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 101.917% |
| AEON Biopharma, Inc. | - USD | Infinity% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 27.64% |
| Sesen Bio, Inc. | 40 Million USD | 106.679% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | -799.504% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 33.66% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 72.073% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 118.974% |
| Athira Pharma, Inc. | -969 Thousand USD | -175.699% |
| Vaccinex, Inc. | -16 Million USD | 83.307% |
| HCW Biologics Inc. | -574.82 Thousand USD | -364.756% |
| XOMA Corporation | 3.86 Million USD | 169.193% |
| Nektar Therapeutics | 53.47 Million USD | 104.996% |
| Arvinas, Inc. | 71.8 Million USD | 103.721% |
| Tevogen Bio Holdings Inc. | - USD | Infinity% |
| Merus N.V. | -83.46 Million USD | 96.799% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 95.744% |
| Quince Therapeutics, Inc. | -322 Thousand USD | -729.667% |
| Rezolute, Inc. | -36 Thousand USD | -7320.911% |
| Clene Inc. | 533 Thousand USD | 601.225% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | -207962.928% |
| BeyondSpring Inc. | 1.75 Million USD | 252.572% |
| Synlogic, Inc. | -1.92 Million USD | -38.853% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | -7120.346% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 57.809% |
| Peak Bio, Inc. | 367.76 Thousand USD | 826.415% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 85.912% |
| Krystal Biotech, Inc. | 47.6 Million USD | 105.612% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 101.893% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 153.165% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | -3.179% |
| MannKind Corporation | 136.19 Million USD | 101.962% |
| Ikena Oncology, Inc. | -50.49 Million USD | 94.709% |
| Cyclerion Therapeutics, Inc. | - USD | Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 102.455% |
| Gossamer Bio, Inc. | -4.38 Million USD | 39.076% |
| CohBar, Inc. | - USD | Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | -960.13% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | -53330.56% |
| Legend Biotech Corporation | 140.92 Million USD | 101.896% |
| Mural Oncology plc | -2.56 Million USD | -4.072% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -384.851% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | -2571.528% |
| Champions Oncology, Inc. | 20.75 Million USD | 112.872% |
| REGENXBIO Inc. | 53.02 Million USD | 105.038% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 50.13% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | -1288.709% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | -54.245% |
| Vaxart, Inc. | -60.76 Million USD | 95.603% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | -916.641% |
| Cellectis S.A. | 18 Thousand USD | 14941.822% |
| Longeveron Inc. | 221 Thousand USD | 1308.836% |
| Repare Therapeutics Inc. | -80.07 Million USD | 96.664% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.244% |
| Inozyme Pharma, Inc. | -1.29 Million USD | -106.455% |
| Revolution Medicines, Inc. | -399.66 Million USD | 99.332% |
| Nymox Pharmaceutical Corporation | - USD | Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | -7532.937% |
| ArriVent BioPharma, Inc. Common Stock | - USD | Infinity% |
| AN2 Therapeutics, Inc. | - USD | Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | 5552.098% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.031% |
| Denali Therapeutics Inc. | -93.34 Million USD | 97.138% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | -10565.208% |
| Veru Inc. | 7.56 Million USD | 135.31% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | -1669.224% |
| Cingulate Inc. | -582.91 Thousand USD | -358.303% |
| Passage Bio, Inc. | -3.72 Million USD | 28.204% |
| Context Therapeutics Inc. | -12.04 Thousand USD | -22081.402% |
| Exicure, Inc. | -1.42 Million USD | -87.739% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | -597.527% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | 198.836% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | -421.096% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 103.921% |
| Nuvalent, Inc. | - USD | Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | -1685.697% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 95.488% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | 783.255% |
| OmniAb, Inc. | 14.66 Million USD | 118.215% |
| Anew Medical, Inc. | - USD | Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 113.362% |
| Lipocine Inc. | -2.85 Million USD | 6.289% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | -44.955% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 53.172% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | -77.358% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 103.547% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | -4010.043% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 103.169% |
| Ocugen, Inc. | -33.53 Million USD | 92.034% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 15.511% |
| Q32 Bio Inc. | 578 Thousand USD | 562.202% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | -908.124% |
| Alumis Inc. Common Stock | -1.28 Million USD | -108.063% |
| Equillium, Inc. | 35.95 Million USD | 107.43% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | -56.504% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | 633.581% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | -64523.319% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -931.478% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 731.997% |
| Dominari Holdings Inc. | 2.03 Million USD | 231.021% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | -1356.104% |
| vTv Therapeutics Inc. | -13.59 Million USD | 80.349% |
| Bio-Techne Corporation | 773.07 Million USD | 100.346% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 115.425% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 100.58% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | -128.531% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 88.859% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 122.839% |
| Nkarta, Inc. | -5.86 Million USD | 54.481% |
| BioCardia, Inc. | -7.24 Million USD | 63.146% |
| Iterum Therapeutics plc | -1.75 Million USD | -52.659% |